GDI1 Antibody
Description
Introduction to GDI1 Antibody
GDI1 antibodies are immunological reagents designed to detect and study the GDI1 protein, encoded by the GDI1 gene located on human chromosome Xq28 . GDI1 modulates Rab GTPases—key regulators of intracellular vesicle transport—by inhibiting GDP dissociation and recycling Rab proteins between membranes and the cytosol . These antibodies are critical for investigating GDI1's roles in neurological disorders and cancer .
Antibody Characteristics
GDI1 antibodies vary in clonality, reactivity, and applications:
-
Immunogen: Most antibodies target recombinant fragments (e.g., aa 1–200 or 415–443) .
-
Cross-Reactivity: Some antibodies (e.g., 10249-1-AP) recognize both GDI1 and GDI2, while others (e.g., 55214-1-AP) are GDI1-specific .
Protein Localization and Expression
-
Western Blot (WB): Used to detect GDI1 in lysates from brain (SH-SY5Y, U87-MG), HeLa, and colorectal cancer tissues .
-
Immunohistochemistry (IHC): Validates cytoplasmic and membrane GDI1 expression in human brain and prostate cancer samples .
-
Flow Cytometry: Quantifies intracellular GDI1 levels in permeabilized cells .
Functional Studies
-
Rab Protein Regulation: Antibodies like 130011 (Synaptic Systems) confirm GDI1's role in dissociating GDP-bound Rab proteins (e.g., Rab3A, Rab5A) from membranes .
-
Cancer Research: Overexpression of GDI1 correlates with poor differentiation and survival in colorectal cancer (CRC). High GDI1 levels reduce chemotherapy efficacy in stage III CRC patients :
| GDI1 Expression | Hazard Ratio (Death) | Chemotherapy Benefit |
|---|---|---|
| Low | 0.22 (95% CI: 0.09–0.56) | Significant risk reduction |
| High | 0.63 (95% CI: 0.35–1.14) | No significant benefit |
Neurological Disorders
-
Mutations in GDI1 cause X-linked intellectual disability (MRX41, MRX48) .
-
Reduced Rab3A activation in schizophrenia is linked to GDI1 dysfunction .
Cancer Biomarker Potential
-
CRC Prognosis: High GDI1 mRNA/protein levels predict aggressive tumor behavior and poor survival .
-
Therapeutic Target: GDI1-enriched pathways (e.g., metastasis, vesicle transport) are druggable candidates .
Validation and Limitations
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Research indicates that GDI1 regulation in the morphogenesis of seedlings and leaf pavement cells could be influenced through modulation of the ROP signaling pathways. Phosphorylation of GDI1 by CPK3 is crucial for developmental regulation. PMID: 23846874
Q&A
GDI1 (GDP Dissociation Inhibitor 1) antibodies are critical tools for studying Rab protein recycling and synaptic vesicle dynamics. Below are structured FAQs addressing both foundational and advanced research considerations, informed by current methodologies and challenges in antibody-based investigations.
Advanced Research Challenges
How to resolve contradictory IHC results between brain and non-neural tissues?
-
Approach:
Common pitfalls:
-
Stromal cell contamination in tumor-adjacent "normal" tissue .
-
Post-mortem degradation artifacts in neural tissues (use fresh-frozen sections with protease inhibitors) .
What strategies optimize GDI1 detection in multiplex assays?
-
Sequential staining: Block residual HRP activity with 3% H₂O₂ after DAB development to prevent cross-reactivity .
-
Spectrally distinct fluorophores: Use Alexa Fluor 647 (far-red) for GDI1 paired with FITC-labeled synaptic markers (e.g., synaptophysin) .
How to design cross-species comparative studies using GDI1 antibodies?
-
Guidelines:
Technical Optimization Tables
Table 1: Antibody performance across applications
| Application | Recommended Dilution | Buffer Compatibility Issues |
|---|---|---|
| WB (denaturing) | 1:1,000 | Avoid β-mercaptoethanol >0.1% |
| IF (fixed cells) | 1:200 | Triton X-100 ≥0.3% improves penetration |
Table 2: Troubleshooting aberrant WB bands
| Issue | Likely Cause | Solution |
|---|---|---|
| ~75 kDa band | Dimerization | Add fresh 2% SDS to loading buffer |
| Smearing below 50 kDa | Proteolysis | Include 1x EDTA + protease inhibitor cocktail |
